Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France.

Case studies - 29 mai 2019

Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France.

In the context of PRIME, a European biotechnological company entrusted BlueReg CMC team with the task of bringing the available quality data package of a synthetic peptide to global registration prerequisites for the next steps of development (the Compassionate use program in France, Phase III global program, registration in Europe and US) and to write the Quality part of the IMPD for early access submission in France.

 

Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :


BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
Any inquiries, correction or declaration of event related to personal data processed should be sent to: our contact page
Learn more

Découvrez notre dernier livre blanc

En savoir plus